I think I’m finally up to speed here with the MoA and list of indications. Since we’re working with a CCR5 antagonist that does not disrupt normal immune function - you can add virtually every condition ending in ‘itis’ to this list. Inflammation is the cause of most, if not all age-related diseases, and since leronlimab restores immune/inflammatory homeostasis - there is a theoretical application for every inflammatory condition. A “generational drug”. Thoughts?
News 
Market Data 
Discover 
